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Abstract 
BCL2 is the milestone of apoptosis-regulatory 
genes. It contributes to tumorigenesis by blocking 
programmed cell death as such, promoting cell 
survival. The aberrant expression of BCL2 gene is 
strongly associated with resistance to chemotherapy 
and radiation. This review outlines the structure, 
function, and role of BCL2 gene in cancer. 
Keywords 
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Identity 
Other names 
Apoptosis Regulator, Protein Phosphatase 1, 
Regulatory Subunit 50, PPP1R50 
HGNC (Hugo) 
BCL2 
Location 
18q21.33 
Local order 
Telomere to centromere orientation. 
Figure 1 BCL2 (18q21) PAC 248E24 - Courtesy 
Mariano Rocchi 
Note 
BCL2 is a proto-oncogene, initially cloned as the 
result of its consistent involvement by 
t(14;18)(q32;q21) in lymphoma where its 
transcription becomes driven by the 
immunoglobulin heavy chain (IGH) gene enhancer 
on chromosome 14q32, subsequently leading to 
constitutive expression of BCL2 in B-cell clones 
(Tsujimoto et al, 1984, Bakhshi et al, 1985). In 
contrast to many oncogenes, BCL2 does not trigger 
cell proliferation but promotes cell survival 
specifically by preventing programmed cell death, 
apoptosis (Vaux and Adams 1988). 
DNA/RNA 
Description 
The human BCL2 gene has a three exon structure 
with an untranslated first exon, a facultative 220 bp 
intron I, and a large 370 kb intron II. The native 
BCL2 gene has a long 3' untranslated regions and 
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two distinct promoters, P1 and P2. The main 
promoter region, P1, is a TATA-less, GC-rich 
promoter containing multiple transcriptional start 
sites and located 1386-1423 bp upstream of the 
translation start site.  The use of alternative promoter 
results in mRNAs comprised of exons II/III or 
I/II/III. The t(14;18) translocation in B-cells  
generates heterogeneous 4.2 - 7.2 kb BCL2-IGH 
chimeric mRNAs resulting from alternative BCL2 5' 
exons and varied IGH 3' untranslated regions. The 
t(14;18) does not interrupt the BCL2 open reading 
frame, however, inappropriately high levels of 
BCL2-IGH mRNAs are present. The native BCL2 
and BCL2-IGH fusion mRNAs demonstrate the 
same 2.5-hour short half-life (Clearly et al, 1986, 
Tsujimoto et al1986, Seta et al1988) 
Protein 
 
 
 
Description 
The BCL2 gene encodes a 26 kd protein consisting 
of 239 amino acids with a single highly hydrophobic 
domain at its C-terminus, which enables it to localize 
mainly in the mitochondrial outer membrane, and to 
a lesser extent in the nuclear envelope and the 
membrane of the endoplasmic reticulum (Chen-
Levy 1989). The main role of BCL2 protein is to 
maintain the integrity of the mitochondrial 
membrane, preventing cytochrome c release and its 
subsequent binding to APAF1 (apoptosis activating 
factor-1). The protein contains all four BCL2 
homology (BH) domains (BH1 to BH4). BH1, BH2 
and BH3 constitute the hydrophobic cleft through 
which the protein interacts and forms homo- and 
heterodimers with the pro-apoptotic members of the 
BCL2 family of proteins (Thomadaki 2006, Reed 
2006). BCL2 increases the survival kinetics of the 
cell specifically by blocking apoptosis. Thus it 
prevents the cell from going into suicidal activities 
that usually require ATP, new RNA, and protein 
synthesis, and inducing a variety of cellular ultra-
structural changes such as cell shrinkage, nuclear 
fragmentation, and DNA degradation. 
Expression 
BCL2 expression is widespread in immature tissues 
prenatally whereas its expression becomes highly 
restricted with maturation. BCL2 is extensively 
expressed in immature B-cells and memory B cells 
but is temporarily down-regulated in germinal center 
B-cells, partially because of repression by BCL6. 
High levels of BCL2 have been detected in thymus 
throughout the medulla, in spleen and in lymph 
nodes as well as early in the embryonic kidney. 
Decrease in its expression levels is observed in 
motor-neurons as well as in pre-B cells being 
prepared to differentiate (Thomadaki 2006). 
Function 
 BCL2 Protein Family and Apoptosis 
The BCL2 family is a prototype of a large family of 
evolutionarily related proteins that share a high 
degree of homology although they exert different 
functions. This family consists of 25 pro-apoptotic 
and anti-apoptotic members which interact to 
maintain a balance between newly forming cells and 
old dying cells. These proteins are localized to the 
membrane of mitochondria and endoplasmic 
reticulum, operating as guardians of these organelles 
(Thomadaki 2006, Reed 2008, Aki etal 2014)). 
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BCL2 family proteins play central roles in cell death 
regulation and can regulate diverse cell death 
mechanisms including apoptosis, necrosis and 
autophagy. They are the key regulators of the 
mitochondrial pathway of apoptosis. This pathway is 
required for normal embryonic development and for 
preventing cancer. These proteins control the 
permeabilization of the mitochondrial outer 
membrane (MOM) that releases cytochrome c and 
other apoptotic factors into the cytosol. BCL2 family 
proteins share up to four BCL2 homology domains 
(BH1, BH2, BH3, & BH4) and are generally divided 
into two categories, anti-apoptotic and pro-apoptotic 
proteins based on their intracellular function and 
sequence homology. The anti-apoptotic proteins, 
BCL2, BCL2L1 (BCL-XL), BCL2L2 (BCL-W), 
MCL1, BCL2A1 (A1/BFL-1), share homology 
within four domains (BH1-4). These proteins form a 
characteristic helical bundle fold, which is critical 
for their ability to bind to the pro-apoptotic BCL2 
family members and thereby exert their antiapoptotic 
function. The pro-apoptotic proteins such as BAX, 
BAK1, and BOK share BH1-3 domains whereas 
other pro-apoptotic proteins, such as BCL2L11 
(BIM), BAD, and BID, contain only the BH3 
domain and are known as BH3-only proteins (Figure 
3). In normal situations, the BH3-only proteins are 
inactive or exist at low levels in the cell. However, 
in the presence of apoptotic stimuli the BH-only 
proteins become activated by post-translational 
modifications or their expression are increased. The 
stimulation of BH3-only proteins induces BAX-
BAK oligomerization. After their oligomerization, 
BAX and BAK directly cause MOM 
permeabilization, a critical step in apoptosis (Aki et 
al 2014). The role of anti-apoptotic BCL2 proteins is 
to neutralize pro-apoptotic BH3-only proteins and 
thus inhibit their effect on BAX-BAK activity and 
MOM permeabilization. The balance between pro-
survival and pro-death BCL-2 proteins is a major 
factor in determining if cells undergo apoptosis in 
response to cell stress. 
 Control of Proliferation by BCL2  
Although BCL2-family proteins are key players in 
the control of mitochondria-based apoptosis, they 
can also control cell proliferation. High levels of 
BCL2 protein were reported to be associated with a 
lower proliferative capacity of human lymphoma, 
suggesting a negative control on proliferation. The 
anti-proliferative effect of BCL2 acts mainly at the 
level of the G0/G1 phase of the cell cycle. Deletions 
and point mutations in the BCL2 gene show that in 
some cases the anti-proliferative activity of BCL2 
can be dissociated from its anti-apoptotic function 
(Bonnefoy et al, 2004). This indicates that the effect 
of BCL2 on cell cycle progression can be a direct 
effect and not only a consequence of its anti-
apoptotic activity. BCL2 appears to mediate its anti-
proliferative effect by acting on both signal 
transduction pathways (NFAT, ERK) and on 
specific cell cycle regulators. In addition, BCL2 
cooperated with MYC to promote proliferation of B-
cell precursors. 
 
Figure 3  BCL-family proteins have 1-4 domains (BH1, BH2, BH3 or BH4) and a transmembrane domain (TM). 
Anti-apoptotic BCL2-family members contain all four BH domains. Proapoptotic BCL2-family members are 
either multi-domain or BH3-only proteins.
 
Implicated in 
Top note 
Apoptosis is essential for normal embryonic 
development, maintenance of tissue homeostasis, 
and development and function of the immune 
system. In contrast, processes that interfere with 
normal apoptosis promote cell survival and, 
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potentially, oncogenesis. Therefore, dysregulation of 
BCL2 family has a major role in tumor formation. 
The BCL2 family is also involved in other diseases, 
such as autoimmune, infectious and 
neurodegenerative disorders. The autoimmune  
 
disease such as type I diabetes can be caused by 
defective apoptosis, and schizophrenia may result 
from an abnormal ratio of pro- and anti-apoptotic 
factors (Strasser et al, 2011).  On the other hand, 
there is increasing evidence that BCL2 family 
proteins also have additional functions in other 
cellular processes, such as mitochondrial 
morphology and metabolism, which remain largely 
unexplored.  Apoptosis is regulated by a balance of 
pro-apoptotic factors and anti-apoptotic factors. 
t(14;18)(q32;q21) 
The t(14;18) Breakpoints in Lymphoma 
The t(14;18)(q32;q21) constitutes the most common 
chromosomal translocation in human lymphomas, 
being present in over 85% of follicular lymphoma 
(FL) and in up to 30% of diffuse large B-cell 
lymphoma (DLBCL). BCL2 is normally located on 
chromosome 18q21.33 in a telomere to centromere 
orientation. The molecular consequence of the 
t(14;18) juxtaposes of the BCL2 gene next to IGH 
locus on the der(14) chromosome, in the same 
transcriptional orientation as the IGH gene. The 
breakpoints on chromosome 18 are clustered with 
50-60% fall within a 2.8 kb major breakpoint region 
(MBR), located in the untranslated 3? UTR of the 
BCL2 gene, and another 25% falls in the minor 
cluster region (MCR) (Bakhshi 1987, Willis and 
Dyer 2000). Others cluster within a third, 
intermediate cluster region midway between the 
MBR and MCR while other breakpoints have been 
described scattered through this region. In rare 
variant translocations involving the IG light chain 
loci, t(2;18)(p12;q21) and t(18;22)(q21;q11.2), the 
breakpoints are located in the 5? noncoding region 
of the BCL2 gene. The breakpoints on chromosome 
14 occur most commonly just 5? of IGH JH segments 
within sequences that typically show evidence of 
exonucleolytic "nibbling", N-bp additions, and D 
segment addition, events that occur normally during 
attempted V(D)J recombination. Less commonly, 
IGH breakpoints may occur at sites 3? of the JH 
segments, or rarely even in IG switch regions. BCL2 
mRNA expression is up-regulated in the translocated 
allele through the action of IGH E[] enhancer 
sequences, which are highly active in germinal 
center B cells. In the cases of rearrangements falling 
in the MBR, a BCL2/IGH fusion mRNA transcript 
is produced whereas rearrangements in the MCR 
lead to increased levels of a normal BCL2 mRNA 
(Aster and longtine 2002). The t(14;18) translocation 
or its variants does not interrupt the protein-encoding 
region of BCL2 gene so that the normal and the 
translocated alleles produce the same-sized, 26-kd 
protein, a member of a family of proteins involved in 
the regulation of apoptosis. The somatic 
hypermutation mechanism associated with the IGH 
gene often induces mutations in the BCL2 gene 
which may further dysregulate its expression and can 
also lead to point mutations in the coding regions of 
the BCL2 protein (Seto 1988, Tanaka et al 1992). 
Therefore, a subset of t(14;18) positive lymphomas 
do not express intact BCL2 protein due to somatic 
mutations of the gene. 
The majority of follicular lymphomas in adults 
depend on BCL2 overexpression which is almost 
always the result of t(14;18) translocation or its 
variants. BCL2 overexpression sustains cell survival 
but is not sufficient for FL development, thus other 
genetic lesions or epigenetic events are required. 
This is supported by the observation that BCL2 
transgenic mice develop polyclonal hyperplasia of 
mature, long lived non-dividing B cells. With time, 
a fraction of BCL2 transgenic mice develops 
aggressive, clonal large cell lymphomas, which have 
acquired additional genetic lesions (McDonnell et al 
1988). 
Cytogenetics 
 Diagnostic use of BCL2  
Fluorescence in situ hybridization (FISH) is widely 
used in clinical laboratories to detect BCL2 gene 
rearrangement in fresh tissue and paraffin embedded 
tissue sections using dual color translocation DNA 
probes (Figure 4). BCL2 protein expression by 
immuno-histochemistry represents a rapid and 
inexpensive method to identify BCL2 
overexpression. In normal tissue, BCL2 antibodies 
react with B-cells in the mantle zone, as well as some 
T-cells. Because BCL2 expression is down-
regulated in normal germinal centers, the presence of 
BCL2 protein can help to distinguish follicular 
lymphomas from reactive follicular hyperplasia. 
However, positive cells increase considerably in 
follicular lymphoma, as well as many other forms of 
cancer. In some cases, the presence or absence of 
BCL2 staining in biopsies may be significant for the 
patient's prognosis or likelihood of relapse. 
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Figure 4 Karyotype from follicular lymphoma showing t(14;18)(q32;q21) [arrow]; Insert: FISH with IGH/BCL2 
DNA probes showing a double fusion signals confirming t(14;18) [red &green fused signals] 
BCL2 Expression in Cancer   
BCL2 is upregulated in almost 50% of all human 
cancers, consistent with its role as an apoptotic 
regulator (Cory et al, 2003, Yip and Reed, 2008, 
Reed 2008). The majority of small cell lymphoma 
such as chronic lymphocytic leukemia (CLL), 
marginal cell lymphoma, and mantle cell lymphoma, 
over-express BCL2, although less than 5% of those 
patients have detectable BCL2 gene rearrangement 
(Hanada et al, 1993). Increased expression of BCL2 
is also found in nearly all patients with acute 
lymphocytic leukemia and frequently in acute 
myeloid leukemia (Yip and Reed 2008). Most of 
adult FL cases have overexpression of BCL2 protein 
however; the pediatric type FL is negative for BCL2 
expression.  Approximately 30% of DLBCL patients 
are categorized as having relatively high BCL2 
expression (Monni et al, 1997).  BCL2 may also play 
a role in non-hematologic tumors, and inappropriate 
expression has been observed in solid tumors such as 
prostate, breast, and small cell and non-small cell 
lung cancers. In small cell lung cancer, high BCL2 
expression in >90% of patients have been reported 
(Hellemans et al 1995, Jiang et al 1995, Anagnostou 
et al 2010, Henriksen et al 1995). Ovarian, 
neuroblastoma, bladder, colorectal, and some head 
and neck cancers have all exhibited high expression 
of BCL2.  
 
 Mechanisms of BCL2 Activation   
Besides chromosomal translocations as a key 
mechanism for activation of the BCL2 gene in 
lymphoma, overexpression as a result BCL2 
amplification has been demonstrated in non-
Hodgkin's lymphomas and small cell lung cancers 
(Monni O, 1997). Other contributing mechanisms 
are deletion of endogenous microRNAs (miRs) such 
as MIR195, MIR24-2 and MIR-365B that normally 
repress BCL2 gene expression (Cimmino et al.,  
2005), This mechanism has been documented in 
CLL, where the genes encoding MIR15 and miR16 
become deleted or inactivated by mutations in >70% 
of these leukemia. Gene hypomethylation is an 
alternative mechanism implying altered epigenetic 
regulation of BCL2 is in some malignancies (Hanada 
et al, 1993).  In addition, tumor associated viruses, 
such as Epstein-Barr virus (EBV) and human herpes 
virus 8 (HHV8 or Kaposi's sarcoma-associated 
herpes virus), encode proteins that are homologues 
of BCL2, and provoke similar anti-apoptotic 
functions (Henderson et al, 1993).  
 
 Expression of BCL2 and Prognosis   
Multiple studies have shown that high levels of 
BCL2 gene expression is a negative risk factor 
correlated with severity of malignancy. Elevated 
expression of BCL2 in AML was shown to be 
associated with poor clinical response to 
chemotherapy (Campos et al, 2005). BCL2 
expression correlates negatively with overall 
survival within a specific subgroup of DLBCL (Iqbal 
et al, 2006).  Additionally, several studies have 
demonstrated a correlation between elevated BCL2 
expression and poor prognosis in melanoma, breast, 
prostate, small cell lung, colorectal and bladder 
cancers (Anagnostou et al, 2010). Further studies 
have proven that higher BCL2 expression leads to 
resistance to chemotherapy and radiation (Reed 
2008, Review).  
 
 BCL2 for Targeted Therapy   
Some cancers, particularly non-Hodgkin lymphoma, 
are dependent on BCL2 for survival. BCL2 is also 
involved in the development of resistance to 
chemotherapeutic agents, further stressing the 
importance of targeting the BCL2 gene in cancer 
therapeutics.  Numerous approaches have been 
developed to block or modulate the production of 
BCL2 at the RNA level, at the protein level, or at the 
DNA level. From a clinical perspective, treatment 
with novel, potent BCL2 inhibitors either alone or in 
combination with conventional therapies hold 
significant promise for providing beneficial clinical 
outcomes. The BCL2 targeted drug has the potential 
BCL2 (B-Cell Leukemia/Lymphoma 2)  
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to enhance cell killing when used alone or in 
combination with traditional cytotoxic agents, which 
may lead to greater efficacy and reduce toxicity of 
chemotherapy (Ebrahim et al 2016, Delbridge et al, 
2016).  
 
 Antisense Oligonucleotides (ASOs)   
Antisense technology involves the use of a sequence 
that is complementary to a specific mRNA which 
inhibits its expression and subsequently induces a 
blockade in the transfer of genetic information from 
DNA to protein. Oblimersen sodium, an example of 
ASO agent, is an 18-base antisense phosphorothioate 
oligonucleotide compound designed to specifically 
target the first six codons of the human BCL2 mRNA 
sequence, resulting in degradation of BCL2 mRNA 
and a subsequent decrease in BCL2 protein 
translation and intracellular concentration (Herbst et 
al, 2004). Oblimersen has been evaluated for 
suitability of the treatment of a number of cancers, 
including small cell lung cancer, prostate cancer, 
renal cell carcinoma, as well as non-Hodgkin 
lymphomas. This compound is already well 
advanced in clinical trials for the treatment of 
refractory CLL, multiple myeloma and melanoma. 
Studies showed that treatment with Oblimersen 
alone resulted in some long-term disease-free 
survival, while combination therapy with 
cyclophosphamide resulted in long-term disease-free 
survival with no histological or molecular evidence 
of lymphoma. Of note, treatment with antisense 
oligonucleotides lowers the concentration of other 
chemotherapies required for treatment, decreasing 
side effects and toxicity.  
 
 Small-Molecule Protein Inhibitors (SMIs)   
Small-molecule inhibitors (SMIs) are a group of 
drugs designed to mimic BH3-only proteins to 
inhibit the action of anti-apoptotic BCL2 proteins. 
They compete with pro-apoptotic BCL2 to occupy 
BH3 docking grooves on the surfaces of anti-
apoptotic family members, thus functioning as 
valuable anti-neoplastic drugs. One such drug is 
Obatoclax (GX15-070) D, a new experimental pan 
inhibitor of BCL2-family proteins, particularly to 
MCL1, as many hematologic malignancies depend 
on this protein for survival. Obatoclax can induce 
oligomerization of BAK in the mitochondria, 
interrupting its function, and activate caspases 
leading to cell death and cell cycle arrest. Obatoclax 
was shown to overcome drug resistance and 
potentiate the efficacy of traditional 
chemotherapeutic agents.  
 
 DNA interference (DNAi)   
DNAi therapeutic drugs, such as PNT2258, are a 
class of nucleic acid-based therapy that contain 
sequences designed against noncoding, non-
transcribed regions of genomic DNA upstream of 
gene transcription initiation sites, thus effectively 
blocking its transcription.  DNAi can interact with 
genomic DNA leading to an apoptotic cell death 
cascade by gene silencing. This approach is aimed at 
blocking BCL2 gene transcription. Evaluations of 
this technology in preclinical and early clinical 
studies are very encouraging and strongly support 
further development of DNAi as cancer therapeutics. 
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